[{"orgOrder":0,"company":"GC Biopharma","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HM15421","moa":"GLP-1R","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GC Biopharma \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Donaperminogene Seltoplasmid","moa":"Hepatocyte growth factor (HGF)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"ENCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ENCell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ENCell \/ Undisclosed"},{"orgOrder":0,"company":"ENCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ENCell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ENCell \/ Undisclosed"}]